Science and Technology

Analytical Framework for Examining the Value of Antibacterial Products. A.6.2 Current Treatment

According to American Thoracic Society/Infectious Diseases Society of America guidelines, patients with no known risk factors for multi-drug resistant pathogens and early onset of disease may receive initial intravenous treatment with antibacterial drugs such as ceftriaxone, levofloxacin, moxifloxacin, ciprofloxacin, ampicillin/sulbactam, or ertap

Analytical Framework for Examining the Value of Antibacterial Products. A.6.1 Background

Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are acute infections of the that occur, by definition, in hospitalized patients. The bacteria that commonly cause HABP and VABP include Gram-negative bacilli including Pseudomonas aeruginosa , Staphylococcus aureus , Streptococcus pneumoniae, and

Analytical Framework for Examining the Value of Antibacterial Products. Hospital Acquired Bacterial Pneumonia (HABP)/Ventilator Associated Bacterial Pneumonia (VABP)

Analytical Framework for Examining the Value of Antibacterial Products. A.5.2 Current Treatment

Treatment often involves empiric broad-spectrum antibacterial drug therapy, initially. Modifications of the antibacterial drug regimen can be made after urine culture and sensitivity analysis results are obtained. Mild to moderately ill patients may be treated in an outpatient setting with oral antibacterial drugs, such as norfloxacin or ciproflox

Analytical Framework for Examining the Value of Antibacterial Products. A.5.1 Background

Complicated urinary tract infections (CUTIs) are those infections diagnosed in individuals with structural or functional abnormalities of the genitourinary tract. Factors that may contribute to complicated infections include indwelling catheters, neurogenic bladder, renal failure, obstructive uropathy, urinary retention, and pregnancy. It is est

Analytical Framework for Examining the Value of Antibacterial Products. Complicated Urinary Tract Infections (CUTI)

Analytical Framework for Examining the Value of Antibacterial Products. A.4.3 List of Drugs Used in Determining Different Market Size Estimates

Appendix Table 4: List of Drugs Used in Determining Different Market Size Estimates for CIAI

Analytical Framework for Examining the Value of Antibacterial Products. A.4.2 Current Treatment

CIAIs are likely to be managed in an inpatient setting, as successful treatment is dependent on both source control (e.g., surgical drainage and definitive management of the source) and antimicrobial treatment.

Analytical Framework for Examining the Value of Antibacterial Products. A.4.1 Background

Intra-abdominal infections (IAIs) comprise a wide range of pathological conditions, such as appendicitis, diverticulitis, gastroduodenal perforation, cholangitis, cholecystitis, and pancreatitis. IAIs are typically subcategorized as either uncomplicated or complicated, although the distinction between them is not always clear. Generally, uncompl

Analytical Framework for Examining the Value of Antibacterial Products. Complicated Intra-abdominal Infection (CIAI)

Analytical Framework for Examining the Value of Antibacterial Products. A.3.3 List of Drugs Used in Determining Different Market Size Estimates

Appendix Table 3: List of Drugs Used in Determining Different Market Size Estimates for CABP

Analytical Framework for Examining the Value of Antibacterial Products. A.3.2 Current Treatment

Patients with CABP are started on antibacterial drugs as soon as possible. Because the causative organism is difficult to identify, physicians choose antibacterial drugs for the most common pathogen(s) associated with the condition and the severity of illness. Most CABP patients improve with antibacterial drug treatment.

Analytical Framework for Examining the Value of Antibacterial Products. A.3.1 Background

Community-acquired bacterial pneumonia (CABP) is an acute infection that involves the lungs. CABP is associated with symptoms such as fever or, chills, rigors, cough, chest pain, or dyspnea, and accompanied by the presence of a new lobar or multilobar infiltrate on a chest radiograph. Streptococcus pneumoniae is the most commonly identified

Analytical Framework for Examining the Value of Antibacterial Products. Community Acquired Bacterial Pneumonia (CABP)

Analytical Framework for Examining the Value of Antibacterial Products. A.2.3 List of Drugs Used in Determining Different Market Size Estimates

Appendix Table 2: List of Drugs Used in Determining Different Market Size Estimates for ABSSSI

Analytical Framework for Examining the Value of Antibacterial Products. A.2.2 Current Treatment

While uncomplicated SSTIs may be treated in the outpatient setting with oral dicloxacillin–flucloxacillin or cephalexin (or, alternatively, penicillin, amoxicillin/clavulanic acid, macrolides, tetracyclines, or clindamycin), more serious SSTIs often require parenteral administration of antimicrobial agents, such as ceftriaxone, clindamycin, pe

Analytical Framework for Examining the Value of Antibacterial Products. A.2.1 Background

Acute bacterial skin and skin structure infections (ABSSSIs) are a subgroup of skin and soft tissue infections (SSTIs), which are commonly occurring microbial infections of the epidermis, dermis and subcutaneous tissues For the purpose of clinical trial design, ABSSSIs are defined by FDA guidance to include such conditions as cellulitis/erysipelas

Analytical Framework for Examining the Value of Antibacterial Products. Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Analytical Framework for Examining the Value of Antibacterial Products. A.1.3 List of Drugs Used in Determining Different Market Size Estimates

Appendix Table 1: List of Drugs Used in Determining Different Market Size Estimates for ABOM

Analytical Framework for Examining the Value of Antibacterial Products. A.1.2 Current Treatment

Physicians may manage patients with ABOM with either a short period (48-72 hours) of observation and then antibacterial therapy if symptoms do not improve or by starting antibacterials immediately. If a decision is made to treat with antibacterial drugs, amoxicillin is recommended as the first antibacterial agent of choice, but alternative drugs

Content by Keyword: Science and Technology